Black Cohosh (Actaea racemosa / Cimicifuga racemosa)

Black cohosh is the most-studied botanical for the menopause transition, and the evidence is genuinely mixed. The form matters more than the dose. The isopropanolic Cimicifuga racemosa extract sold as Remifemin (also called iCR or, in earlier German pharmacology, CR BNO 1055) is what generated the supportive trial data; generic whole-root capsules at 540mg are a different product entirely, with a different active compound load and a much weaker evidence base.

The supportive signal comes from a handful of standardized-extract trials. Osmers 2005 in Obstetrics & Gynecology randomized 304 women with climacteric symptoms to iCR or placebo for 12 weeks; the active arm had significantly greater reductions in the Menopause Rating Scale than placebo. Wuttke 2003 in Maturitas compared BNO 1055 to conjugated estrogens and placebo, with BNO 1055 outperforming placebo on hot flashes and matching estrogen on the Menopause Rating Scale. Bai 2007 in Maturitas replicated the iCR effect in a multicenter Chinese trial against tibolone. Frei-Kleiner 2005 in Maturitas tested an ethanolic Cimicifuga extract and was negative overall but positive in the subgroup with more severe symptoms. The 2021 iCR-specific meta-analysis by Castelo-Branco (Climacteric) pooled 22 trials of iCR specifically and reported a consistent modest benefit on Kupperman Index and hot flash counts; the 2023 update by Sadahiro in Menopause pooled both iCR and non-iCR extracts and saw similar modest pooled effects with substantial heterogeneity.

The skeptical signal is real and equally important. The Newton 2006 HALT trial in Annals of Internal Medicine - a 1-year, 5-arm randomized trial in 351 women funded by the NIH - found that black cohosh alone, a multibotanical with black cohosh, and a multibotanical with black cohosh plus dietary soy counseling were all statistically indistinguishable from placebo on vasomotor symptom frequency and intensity. Hormone therapy in the same trial worked as expected. HALT did not use the iCR/Remifemin extract; it used a different black cohosh preparation, which is the standard rebuttal from the iCR side. The Cochrane 2012 review by Leach and Moore pooled 16 trials totaling 2,027 women and concluded there was "insufficient evidence to support the use of black cohosh for menopausal symptoms" - acknowledging the iCR signal but flagging the inconsistency, the small-trial bias, and the lack of replication in independent labs. So the honest read is: standardized iCR has a real but modest signal on a 12-week timeframe, and generic black cohosh probably does not.

Mechanism is the second area where common claims need correcting. Black cohosh is repeatedly marketed as a phytoestrogen. It is not, or at least not in any meaningful sense. The current best understanding, from Borrelli's pharmacology reviews and Wuttke's mechanistic work, is that black cohosh acts centrally on serotonergic (5-HT receptors) and dopaminergic pathways, with little to no peripheral estrogen receptor activity at typical doses. The endometrial safety trial by Raus 2006 (Menopause) gave 400 women iCR for 12 months and found no endometrial proliferation, which is consistent with the non-estrogenic mechanism. This matters clinically: women who avoid estrogen for hormone-sensitive reasons (some breast cancer histories, for example) sometimes ask whether black cohosh is "natural estrogen," and the answer is no - but the data in active hormone-sensitive cancer populations remains thin, so an oncology consult is still the right move.

Safety is the third nuanced area. In the 2000s a cluster of hepatotoxicity case reports led the European Medicines Agency and Australia's TGA to require warning labels on black cohosh products. The Mahady 2008 USP review and the 2010 follow-up concluded that the causal relationship between properly identified black cohosh and liver injury was "possible but rare," with most well-documented cases involving products that were adulterated with Asian Cimicifuga species (C. foetida, C. dahurica, C. heracleifolia) rather than authentic Actaea racemosa. The Remifemin/iCR product specifically has been under postmarket surveillance for decades with no clear hepatotoxicity signal. The practical implication: brand and species identity matter, plant identity testing (HPTLC chromatography or DNA) matters, and routine liver function monitoring is reasonable for anyone using black cohosh continuously beyond a few months or who has underlying liver disease. Two non-negotiable contraindications: pregnancy (uterine effects, traditional abortifacient use) and breastfeeding (no safety data). Hormone-sensitive cancer history needs an oncology conversation before starting.